Italia markets closed

Blueprint Medicines Corporation (BPMC)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
44,60-1,06 (-2,33%)
Al 01:51PM EST. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente45,67
Aperto45,42
Denaro44,68 x 1100
Lettera44,72 x 1000
Min-Max giorno44,40 - 45,45
Intervallo di 52 settimane40,78 - 85,67
Volume166.483
Media Volume526.895
Capitalizzazione2,669B
Beta (5 anni mensile)0,64
Rapporto PE (ttm)N/D
EPS (ttm)-11,06
Prossima data utili14 feb 2023 - 20 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A75,53
  • GlobeNewswire

    Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million

    Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in potential sales-based m